Archives
NF 340: Applied Strategies for P2Y11 Antagonist Research Wor
NF 340: Applied Strategies for P2Y11 Antagonist Research Workflows
Overview: Principle and Rationale of NF 340 in Cellular Signaling
As a potent and selective P2Y11 antagonist, NF 340 (sodium (Z)-N-(3,7-disulfonaphthalen-1-yl)-4-methyl-3-(((Z)-((2-methyl-5-((Z)-oxido((3-sulfo-7-sulfonatonaphthalen-1-yl)imino)methyl)phenyl)imino)oxidomethyl)amino)benzimidate), offered by APExBIO, has become instrumental in exploring GPCR signaling pathway dynamics—especially within the domains of immunology research and inflammation pathway modulation. By specifically inhibiting the P2Y11 receptor, NF 340 allows precise interrogation of downstream events, such as cAMP mobilization and myosin light chain phosphorylation, which are critical in processes ranging from immune cell activation to cancer cell migration. The NF 340 product page provides comprehensive data on its selectivity, solubility, and handling requirements, enabling robust experimental design for researchers targeting P2Y receptor signaling.
Key Innovation from the Reference Study
The pivotal study by Liu et al. (2021) uncovers a novel mechanistic link between purinergic signaling and cancer invasiveness. The authors demonstrated that quinolinate phosphoribosyltransferase (QPRT) promotes breast cancer cell migration and invasion via phosphorylation of the myosin light chain. Crucially, pharmacological intervention with NF 340 reversed QPRT-induced invasiveness, highlighting the P2Y11 receptor as a therapeutic and investigative target. For practical assays, this means that NF 340 can be strategically applied to dissect the contribution of P2Y11 in cellular motility, enabling researchers to model, modulate, and quantify signaling events underpinning tumor metastasis or immune activation.
Step-by-Step Workflow: Applied Protocol for NF 340 in Cell Signaling Assays
Optimizing the use of NF 340 begins with careful reagent handling and precise protocol design, ensuring reproducibility and meaningful results in P2Y11-focused studies.
Protocol Parameters
- Stock Solution Preparation: Dissolve NF 340 at up to 19.74 mg/ml in water or DMSO immediately before use; do not store solutions long-term due to stability constraints.
- Working Concentration: Typical final concentrations range from 1 μM to 10 μM for in vitro inhibition of P2Y11-mediated signaling; titrate as needed for cell type and endpoint.
- Incubation Time: Pre-incubate cells with NF 340 for 30–60 minutes prior to stimulation to ensure receptor occupancy.
- Storage Conditions: Store dry NF 340 powder at -20°C in a desiccated environment to preserve potency, as outlined in the product documentation.
Advanced Applications and Comparative Advantages
NF 340’s selectivity as a cell signaling inhibitor targeting the P2Y11 receptor distinguishes it from less specific purinergic antagonists. Its application extends from basic mechanistic studies to advanced models of inflammation pathway modulation and cancer metastasis. For example, in breast cancer research, NF 340 has been leveraged to reverse QPRT-driven cell invasion by blocking downstream GPCR signaling, as demonstrated in the reference study.
Comparing NF 340 to other P2Y antagonists, the Tolrestat Molecules overview highlights its superior selectivity and reproducibility in dissecting P2Y11-specific signaling. Meanwhile, the BHT920Bio article extends its use to translational immunology, emphasizing workflow enhancements and data reliability in inflammation and oncology models. Collectively, these resources position NF 340 as a preferred tool for both hypothesis-driven and high-throughput investigations in GPCR signaling pathway research.
Troubleshooting and Optimization Tips
- Solubility Management: Given its limited solubility in water (<19.74 mg/ml), prepare fresh aliquots in DMSO when higher concentrations are needed. Always vortex vigorously and sonicate briefly if necessary.
- Assay Interference: Watch for potential DMSO effects, especially above 0.1% final concentration in cell-based assays; always include vehicle controls.
- Long-Term Storage: Avoid extended storage of aqueous NF 340 solutions; aliquot powder into single-use vials and minimize freeze-thaw cycles to preserve activity.
- Specificity Confirmation: Employ genetic knockdown or alternative P2Y antagonists as parallel controls to validate that observed effects are truly P2Y11-dependent.
- Batch-to-Batch Consistency: Source NF 340 directly from APExBIO to ensure product integrity and reproducible results, as variations from other suppliers may compromise selectivity and potency.
Cross-Referenced Insights: Extending the Evidence Base
The mechanistic findings of Liu et al. are complemented by the Olaparib.net review, which elaborates on the role of purinergic signaling—and specifically P2Y11—in cancer cell invasiveness and immune modulation. In contrast, the AImmunity article explores broader applications in autoimmune and neuroinflammatory models, reinforcing the translational utility of P2Y11 antagonists like NF 340. Together, these resources provide a comprehensive landscape for researchers aiming to bridge cancer biology with immunological mechanisms through targeted GPCR inhibition.
Future Outlook: Implications for Translational and Preclinical Research
The targeted inhibition of P2Y11 with NF 340 opens new investigative pathways for both fundamental and translational research. As highlighted by Liu et al. and corroborated by multi-domain articles, the ability to modulate GPCR signaling pathways holds promise for unraveling mechanisms of metastasis, immune cell trafficking, and chronic inflammation. However, the use of NF 340 remains confined to preclinical models, as safety and efficacy in humans have not been established (see product details). Continued research leveraging this tool will clarify the prognostic and therapeutic potential of P2Y11 modulation in cancer and immunology, setting the stage for future innovation.